Cochrane · systematic review · CD013399
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
Rank, CU, Lynggaard, LS, Als-Nielsen, B, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
2
No studies
8
Included studies
NR
No studies 8 · 57.1%Ungraded 4 · 28.6%Very low 2 · 14.3%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of Findings Table ‐ Antithrombin concentrates compared to no antithrombin concentrates for thromboprophylaxis in adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
Population: thromboprophylaxis in adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality ‐ Intention‐to‐treat analysis Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates | RR 0.55 [0.26, 1.19] | 1 study · 40 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
First‐time symptomatic venous thromboembolism Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates | no estimate extracted | 1 study · 40 participants | Ungraded |
Major bleeding ‐ not reported Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates | no estimate extracted | NR | No studies |
Venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates | RR 0.1 [0.01, 1.94] | 1 study · 40 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Quality of life ‐ not reported Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates | no estimate extracted | NR | No studies |
Asymptomatic venous thromboembolism Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates | no estimate extracted | 0 studies · 0 participants | Ungraded |
Clinically relevant non‐major bleeding ‐ not reported Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Enoxaparin compared to no enoxaparin for thromboprophylaxis in adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
Population: adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality ‐ not reported Summary of Findings Table ‐ Enoxaparin vs no enoxaparin | no estimate extracted | NR | No studies |
First‐time symptomatic venous thromboembolism Summary of Findings Table ‐ Enoxaparin vs no enoxaparin | no estimate extracted | 1 study · 224 participants | Ungraded |
Major bleeding Summary of Findings Table ‐ Enoxaparin vs no enoxaparin | no estimate extracted | 1 study · 224 participants | Ungraded |
Thrombosis‐related mortality ‐ not reported Summary of Findings Table ‐ Enoxaparin vs no enoxaparin | no estimate extracted | NR | No studies |
Quality of life ‐ not reported Summary of Findings Table ‐ Enoxaparin vs no enoxaparin | no estimate extracted | NR | No studies |
Asymptomatic venous thromboembolism ‐ not reported Summary of Findings Table ‐ Enoxaparin vs no enoxaparin | no estimate extracted | NR | No studies |
Adverse events: clinically relevant non‐major bleeding / heparin‐induced thrombocytopenia ‐ not reported Summary of Findings Table ‐ Enoxaparin vs no enoxaparin | no estimate extracted | NR | No studies |